Marshall Wace
BLTE

Marshall Wace’s Belite Bio BLTE Stock Holding History

Marshall Wace’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,700
Closed -$30.8M – 3208
2025
Q4 		$30.8M Buy
192,700
+5,200
+3% +$616K 0.03% 484
2025
Q3 		$13.9M Buy
187,500
+178,014
+1,877% +$11.7M 0.01% 803
2025
Q2 		$547K Buy
+9,486
New +$579K ﹤0.01% 2115
2025
Q1 		– Sell
-5,865
Closed -$370K – 2636
2024
Q4 		$370K Sell
5,865
-2,621
-31% -$173K ﹤0.01% 2163
2024
Q3 		$398K Buy
+8,486
New +$411K ﹤0.01% 2002
2024
Q2 		– Sell
-10,584
Closed -$406K – 2565
2024
Q1 		$406K Sell
10,584
-5,427
-34% -$243K ﹤0.01% 2010
2023
Q4 		$733K Buy
+16,011
New +$615K ﹤0.01% 1584

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's BLTE Position: Q1 2026 in Review

Marshall Wace sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 192,700 shares — an estimated $30.8M sold.

Marshall Wace first reported a position in BLTE in Q4 2023 and held it in 7 quarters. The position peaked at $30.8M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Marshall Wace reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 192,700 Belite Bio shares in Q1 2026, an estimated $30.8M.
  • Marshall Wace first reported a position in Belite Bio in Q4 2023 and held it in 7 quarters.
  • Marshall Wace's Belite Bio position peaked at $30.8M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.